- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.06. | Polyrizon Ltd.: Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics | 1 | GlobeNewswire (USA) | ||
| 12.06. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.05. | Pre-market Movers: Zeo Energy, Elong Power, Brooge Energy, NanoVibronix, Polyrizon | 467 | AFX News | OVERLAND PARK (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.25 A.M. ET).In the Green Zeo Energy Corp. (ZEO) is up over 121% at... ► Artikel lesen | |
| 23.05. | Polyrizon recives Nasdaq delisting notice | 6 | Seeking Alpha | ||
| 23.05. | Polyrizon faces Nasdaq delisting over shareholder dilution | 1 | Investing.com | ||
| 23.05. | Polyrizon Ltd.: Polyrizon Announces Receipt of Nasdaq Delisting Notice | 294 | GlobeNewswire (Europe) | Raanana, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| 22.05. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 12 | SEC Filings | ||
| 21.05. | Polyrizon Announces Encouraging Preclinical Data On Nasal Protection Platform | 1 | RTTNews | ||
| 21.05. | Polyrizon Ltd.: Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform | 1 | GlobeNewswire (USA) | ||
| 14.05. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 13.05. | Polyrizon begins preclinical studies for seizure treatment | 2 | Investing.com | ||
| 13.05. | Polyrizon beginnt präklinische Studien für Krampfanfallbehandlung | 1 | Investing.com Deutsch | ||
| 13.05. | Polyrizon Ltd.: Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment | 430 | GlobeNewswire (Europe) | Raanana, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 02.05. | Polyrizon (PLRZ) Stock Skyrocketed Over 240% Today: What's Going On? | 4 | Benzinga.com | ||
| 30.04. | Polyrizon files to sell 1.51M ordinary shares for holders | 14 | Seeking Alpha | ||
| 25.04. | Polyrizon macht Fortschritte bei Sicherheitsstudie für nasalen Allergieblocker | 3 | Investing.com Deutsch | ||
| 25.04. | Polyrizon advances nasal allergy blocker safety study | 1 | Investing.com | ||
| 25.04. | Polyrizon Ltd.: Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model | 403 | GlobeNewswire (Europe) | Raanana, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative... ► Artikel lesen | |
| 25.04. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 17.04. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings |
1 2 3 4 Weiter >>
61 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,130 | -0,59 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| NOVAVAX | 5,401 | -3,43 % | Novavax Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| PALATIN TECHNOLOGIES | 0,146 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,800 | +1,69 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,840 | -4,05 % | COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders | Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today announced that it has entered into a resolution agreement... ► Artikel lesen | |
| XOMA ROYALTY | 22,600 | -5,04 % | XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend | ||
| T2 BIOSYSTEMS | 0,103 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,150 | -2,49 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort | -Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough, Massachusetts--(Newsfile Corp. -... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| ORAGENICS | 3,650 | +3,84 % | ORAGENICS INC - S-1, General form for registration of securities | ||
| LADRX | - | - | LadRx Corp - 10-Q, Quarterly Report | ||
| VIVUS | - | - | Vivus' Qsymia gains market approval in UAE for obesity treatment | ||
| TENAX THERAPEUTICS | 2,770 | -100,00 % | Tenax Therapeutics, Inc.: Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 0,362 | -6,89 % | Wint Receives Debt Financing From CIBC Innovation Banking | ||
| EDESA BIOTECH | 1,710 | -0,58 % | Edesa Biotech, Inc.: Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results | TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases... ► Artikel lesen |
Das Unternehmen POLYRIZON LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,721 Euro und damit +8,75 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.